Analystreport

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating o

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com